- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07939828
Sarcoma With EWSR1/FUS : POU2AF3 (COLCA2) Fusion : Molecular and Clinicopathologic Characterization of a Case Series. (COL'CHIC)
Sarcomas with the EWSR1/FUS :: POU2AF3 (COLCA2) fusion transcript represent a new molecularly defined entity, first described in 2023 (1). There are 24 cases reported in the literature, including 3 descriptive series totaling 19 cases (1-3). Clinically, this is an aggressive entity affecting patients of varying ages (16-74 years), most commonly located in the sinonasal tract, and capable of involving both bone and soft tissue. A few extrasinonasal cases have also been reported. Histologically, two morphological groups have been described (3): the first group (the rarest) is characterized by a low-grade morphology with non-atypical spindle cells; the second group is morphologically high-grade, featuring spindle, round, or epithelioid cells and possible divergent differentiation (epithelial, neuroendocrine, striated muscle, or bone).
The immunophenotype of these lesions is nonspecific, with variable positivity for various markers such as S100, CD99, AE1/3, CD56, chromogranin, synaptophysin, SATB2, CD117, GFAP, and EMA.
Given the clinical, morphological, and immunohistochemical features of this entity, numerous differential diagnoses can be considered: synovial sarcoma, malignant tumor of the peripheral nerve sheaths, Ewing sarcoma, myoepithelial tumor, biphenotypic sinonasal sarcoma, etc.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: WEINGERTNER Noëlle, MD
- Phone Number: +33388128241
- Email: noelle.weingertner@chru-strasbourg.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
sarcomas
Description
Inclusion Criteria:
- Patient whose test results indicated "the presence of a fusion transcript involving the POU2AF3 gene (formerly COLCA2)"
- Adult patient
- Who has consented to the reuse of their samples for scientific and medical research related to their condition or related conditions
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
SARCOMA
Sarcomas exhibiting an EWSR1/FUS :: POU2AF3 (COLCA2) fusion transcript |
methylation profiling |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clustering Common to methylation analysis and RNA-seq.
Time Frame: 11 months
|
Determine whether sarcomas with the EWSR1/FUS :: POU2AF3 fusion transcript constitute a distinct entity |
11 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC26_0488
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.